# Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

> **NCT01299337** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 29 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** T3

## Key facts

- **NCT ID:** NCT01299337
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2012-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299337, "Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01299337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*